Safety and Temporal Pattern of the Lymphocyte Count During Fingolimod Therapy in Patients With Multiple Sclerosis: Real-World Korean Experience
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Purpose Fingolimod (FTY) inhibits lymphocyte egress from lymphoid organs to cause lymphopenia, but the clinical implications of FTY-induced lymphopenia are not fully understood. We aimed to determine the frequency and severity of lymphopenia during FTY treatment among Korean patients with multiple sclerosis (MS), and its association with infections. Methods We retrospectively reviewed the medical records of patients with MS treated using FTY from 12 referral centers in South Korea between March 2013 and June 2021. Patients were classified according to their nadir absolute lymphocyte count (ALC) during treatment: grade 1, 800–999/μL; grade 2, 500–799/μL; grade 3, 200–499/μL; and grade 4, <200/μL. Results FTY treatment was administered to 69 patients with a median duration of 18 months (range=1–169 months), with 11 patients being treated for ≥7 years. During FTY treatment, mean ALCs were reduced after the first month (653.0±268.9/μL, mean±standard deviation) (p<0.0001) and remained low during treatment lasting up to 84 months. During follow-up, 41 (59.4%) and 7 (10.1%) patients developed grade-3 and grade-4 lymphopenia, respectively. No significant difference was found in age at FTY initiation, sex, baseline ALC, body mass index, or prior disease-modifying treatment between patients with and without grade-4 lymphopenia. Infections were observed in 11 (15.9%) patients, and the frequencies of patients with and without grade-4 lymphopenia were similar. Conclusions FTY treatment induced grade-4 lymphopenia in 10% of South Korean patients with MS, but did not appear to be associated with an increased infection risk.
Abstract
Background and Purpose Fingolimod (FTY) inhibits lymphocyte egress from lymphoid organs to cause lymphopenia, but the clinical implications of FTY-induced lymphopenia are not fully understood. We aimed to determine the frequency and severity of lymphopenia during FTY treatment among Korean patients with multiple sclerosis (MS), and its association with infections. Methods We retrospectively reviewed the medical records of patients with MS treated using FTY from 12 referral centers in South Korea between March 2013 and June 2021. Patients were classified according to their nadir absolute lymphocyte count (ALC) during treatment: grade 1, 800–999/μL; grade 2, 500–799/μL; grade 3, 200–499/μL; and grade 4, <200/μL. Results FTY treatment was administered to 69 patients with a median duration of 18 months (range=1–169 months), with 11 patients being treated for ≥7 years. During FTY treatment, mean ALCs were reduced after the first month (653.0±268.9/μL, mean±standard deviation) (p<0.0001) and remained low during treatment lasting up to 84 months. During follow-up, 41 (59.4%) and 7 (10.1%) patients developed grade-3 and grade-4 lymphopenia, respectively. No significant difference was found in age at FTY initiation, sex, baseline ALC, body mass index, or prior disease-modifying treatment between patients with and without grade-4 lymphopenia. Infections were observed in 11 (15.9%) patients, and the frequencies of patients with and without grade-4 lymphopenia were similar. Conclusions FTY treatment induced grade-4 lymphopenia in 10% of South Korean patients with MS, but did not appear to be associated with an increased infection risk.
참고문헌 (29)
- Brinkmann V, "FTY720(fingolimod)in multiple sclerosis : therapeutic effects in the immune and the central nervous system", Br J Pharmacol, 158, pp.1173~1182 (2009)
- Fragoso YD, "Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod", Mult Scler Relat Disord, 19, pp.105~108 (2018)
- Boffa G, "Fingolimod and dimethyl-fumarate-derived lymphopenia is not associated with short-term treatment response and risk of infections in a real-life MS population", CNS Drugs, 34, pp.425~432 (2020)
- Mehling M, "FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis", Neurology, 71, pp.1261~1267 (2008)
- Francis G, "Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy", Mult Scler, 20, pp.471~480 (2014)
- Kappos L, "A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis", N Engl J Med, 362, pp.387~401 (2010)
- Cohen JA, "Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis", N Engl J Med, 362, pp.402~415 (2010)
- "Gilenya, INN-fingolimod. Summary of product characteristics"[URL]
- "Gilenya 0.5 mg hard capsules"[URL]
- "Gilenya (fingoliimod) prescribing information"[URL]
- Fox EJ, "Lymphocyte counts and infection rates : long-term fingolimod treatment in primary progressive MS", Neurol Neuroimmunol Neuroinflamm, 6, pp.e614~ (2019)
- Kurtzke JF, "Rating neurologic impairment in multiple sclerosis : an expanded disability status scale(EDSS)", Neurology, 33, pp.1444~1452 (1983)
- "Common terminology criteria for adverse events (CTCAE), version 4.0"[URL]
- Warnke C, "Initial lymphocyte count and low BMI may affect fingolimod-induced lymphopenia", Neurology, 83, pp.2153~2157 (2014)
- Ohtani R, "Risk factors for fingolimod-induced lymphopenia in multiple sclerosis", Mult Scler J Exp Transl Clin, 4, pp.2055217318759692~ (2018)
- Kaufmann M, "Real world lab data : patterns of lymphocyte counts in fingolimod treated patients", Front Immunol, 9, pp.2669~ (2018)
- Quirant-Sánchez B, "Predicting therapeutic response to fingolimod treatment in multiple sclerosis patients", CNS Neurosci Ther, 24, pp.1175~1184 (2018)
- Manni A, "Gender differences in safety issues during fingolimod therapy : evidence from a real-life relapsing multiple sclerosis cohort", Brain Behav, 7, pp.e00804~ (2017)
- Calabresi PA, "Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis(FREEDOMS II) : a double-blind, randomised, placebo-controlled, phase 3 trial", Lancet Neurol, 13, pp.545~556 (2014)
- Kappos L, "Fingolimod in relapsing multiple sclerosis : an integrated analysis of safety findings", Mult Scler Relat Disord, 3, pp.494~504 (2014)
- Arvin AM, "Varicella-zoster virus infections in patients treated with fingolimod : risk assessment and consensus recommendations for management", JAMA Neurol, 72, pp.31~39 (2015)
- Winkelmann A, "Indications for varicella zoster and herpes zoster vaccination in multiple sclerosis : current situation", Nervenarzt, 90, pp.1254~1260 (2019)
- Hakiki B, "Withdrawal of fingolimod treatment for relapsing-remitting multiple sclerosis : report of six cases", Mult Scler, 18, pp.1636~1639 (2012)
- Havla JB, "Rebound of disease activity after withdrawal of fingolimod(FTY720)treatment", Arch Neurol, 69, pp.262~264 (2012)
- Hatcher SE, "Rebound syndrome in patients with multiple sclerosis after cessation of fingolimod treatment", JAMA Neurol, 73, pp.790~794 (2016)
- Zecca C, "Half-dose fingolimod for treating relapsing-remitting multiple sclerosis : observational study", Mult Scler, 24, pp.167~174 (2018)
- Lapierre Y, "Canadian experience with fingolimod : adherence to treatment and monitoring", Can J Neurol Sci, 43, pp.278~283 (2016)
- Harty GT, "Discontinuation of diseasemodifying treatments in relapsing-remitting multiple sclerosis – A systematic literature review of observational studies", Eur Neurol Rev, 14, pp.36~43 (2019)
- Zecca C, "Real-life long-term effectiveness of fingolimod in Swiss patients with relapsing-remitting multiple sclerosis", Eur J Neurol, 25, pp.762~767 (2018)